|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Rockefeller University Press,
0021-9525/1998//627 $5.00
The Journal of Cell Biology, Volume 140, Number 3,
, 1998 627-636
Article |
Apoptotic Membrane Blebbing Is Regulated by Myosin Light Chain Phosphorylation
The evolutionarily conserved execution phase of apoptosis is defined by characteristic changes occurring during the final stages of death; specifically cell shrinkage, dynamic membrane blebbing, condensation of chromatin, and DNA fragmentation. Mechanisms underlying these hallmark features of apoptosis have previously been elusive, largely because the execution phase is a rapid event whose onset is asynchronous across a population of cells. In the present study, a model system is described for using the caspase inhibitor, z-VAD-FMK, to block apoptosis and generate a synchronous population of cells actively extruding and retracting membrane blebs. This model system allowed us to determine signaling mechanisms underlying this characteristic feature of apoptosis. A screen of kinase inhibitors performed on synchronized blebbing cells indicated that only myosin light chain kinase (MLCK) inhibitors decreased blebbing. Immunoprecipitation of myosin II demonstrated that myosin regulatory light chain (MLC) phosphorylation was increased in blebbing cells and that MLC phosphorylation was prevented by inhibitors of MLCK. MLC phosphorylation is also mediated by the small G protein, Rho. C3 transferase inhibited apoptotic membrane blebbing, supporting a role for a Rho family member in this process. Finally, blebbing was also inhibited by disruption of the actin cytoskeleton. Based on these results, a working model is proposed for how actin/myosin II interactions cause cell contraction and membrane blebbing. Our results provide the first evidence that MLC phosphorylation is critical for apoptotic membrane blebbing and also implicate Rho signaling in these active morphological changes. The model system described here should facilitate future studies of MLCK, Rho, and other signal transduction pathways activated during the execution phase of apoptosis.
Abbreviations used in this paper: ABP, actin binding protein; BDM, 2,3-butanedione monoxime; MLC, myosin regulatory light chain; MLCK, myosin light chain kinase; ROK, Rho kinase; STS, staurosporine; z-VAD-FMK, z-Val-Ala-Asp-fluoromethylketone.
DYNAMIC membrane blebbing, along with chromatin condensation and DNA laddering are three of the most commonly used criteria for distinguishing apoptosis from other physiological processes (Wyllie et al., 1980). Despite their importance, little is known about mechanisms underlying these conserved events. In most systems, the morphological changes that characterize apoptosis occur shortly before death during a rapid, evolutionarily conserved stage of invariant duration known as the execution phase (Earnshaw, 1995; Jacobson et al., 1997). During the execution phase, the caspase family of proteases is thought to be activated and to cleave specific substrates, rapidly leading to cell death (Chinnaiyan and Dixit, 1996; Nagata, 1997; Nicholson and Thornberry, 1997). The execution phase of apoptosis has resisted biochemical characterization because its onset is markedly asynchronous across a population of cells (Lazebnik et al., 1995; McCarthy et al., 1997; Mills et al., 1997; Messam and Pittman, 1998). Thus, a simple system for synchronizing cells in the execution phase of apoptosis would prove useful for elucidating key signal transduction pathways critical for controlling the biochemical and morphological changes occurring just before death. Recently, McCarthy et al. (1997) reported that inhibition of caspases during apoptosis in Rat-1 fibroblasts resulted in a population of cells that entered into and remained in the execution phase of apoptosis (measured by membrane blebbing), with the same time-course as dying cells but without the appearance of other features of apoptosis (e.g., DNA laddering and chromatin condensation). In the present study, a similar model is described that has allowed us to identify signaling pathways that regulate the dramatic membrane blebbing occurring during the execution phase of apoptosis.
The majority of studies examining the formation of membrane blebs have focused on the role of cytoskeletal proteins. Tumor cells lacking actin binding protein (ABP)1 bleb extensively under normal conditions (Cunningham et al., 1992); cleavage of two other proteins that bind actin, talin and
-actinin, correlate with peroxide-induced blebbing (Miyoshi et al., 1996), and a fourth actin-binding cytoskeletal protein, fodrin, is cleaved by caspases during apoptosis (Martin et al., 1995; Cryns et al., 1996; Nath et al., 1996; Vanags et al., 1996). Numerous studies have focused directly on the role of actin in these apoptotic membrane changes. F actin is necessary for blebbing and eventual "apoptotic body" formation (Cotter et al., 1992), and the concentration of F actin is correlated with bleb size (Cunningham, 1995). F actin is present at the base of blebs during apoptosis (Laster and MacKenzie, 1996; Pitzer et al., 1996; Vemuri et al., 1996), and several groups have proposed that actin is cleaved by caspases during apoptosis (Mashima et al., 1995; Kayalar et al., 1996; McCarthy et al., 1997; see also Song et al., 1997).
Although cytoskeletal proteins including actin seem to be involved in membrane blebbing during apoptosis, there is no direct evidence of a role for myosin as the motor behind these morphological changes (however, it is interesting that microinjection of catalytically active myosin light chain kinase [MLCK] induces membrane blebs; Fishkind et al., 1991). Through interactions with actin, the myosin family of motor proteins is involved in many forms of cell motility. Conventional nonmuscle myosin (myosin II) has been implicated in such basic cellular processes as cytokinesis, stress fiber pulling, maintenance of the cortical actin layer, and secretion of vesicles (for reviews see Grebecki, 1994; Maciver, 1996; Mitchison and Cramer, 1996). Myosin II contractile activity in smooth muscle and nonmuscle cells is stimulated through phosphorylation of myosin regulatory light chain (MLC) on serine 19 by MLCK (Kohama et al., 1996; Gallagher et al., 1997). This phosphorylation catalyzes the interaction of the myosin head with actin and subsequently allows the myosin ATPase to produce sliding force. Recent studies have shown the phosphorylation state of MLC also to be regulated by the small G protein, Rho. Rho is involved in cytoskeletal rearrangement, including cell contraction after lysophosphatidic acid or thrombin stimulation (Jalink et al., 1994; Tigyi et al., 1996; Gebbink et al., 1997), neurite retraction (Jalink et al., 1994; Tigyi et al., 1996; Gebbink et al., 1997), and actin stress fiber formation (Ridley and Hall, 1992; Chrzanowska-Wodnicka and Burridge, 1996). Rho also stimulates Rho kinase (ROK), which phosphorylates and inactivates MLC phosphatase (Noda et al., 1995; Kimura et al., 1996). In addition, ROK and MLCK phosphorylate MLC on the same serine residue (Amano et al., 1996), suggesting that ROK, like MLCK, increases myosin contractile activity.
In this report, we use the caspase inhibitor, z-VAD-FMK to block cell death late in the apoptotic process after initiation of blebbing. This results in a dramatically increased proportion of actively blebbing cells after serum removal. In contrast, this dynamic blebbing does not occur in apoptosis induced by the general kinase inhibitor, staurosporine (STS), suggesting that blebbing may be controlled by phosphorylation. We used the enriched population of blebbing cells after serum removal and z-Val-Ala-Asp-fluoromethylketone (z-VAD-FMK) treatment to characterize key phosphorylation events that occur during the execution phase of apoptosis. Using cellular and biochemical assays, we demonstrate essential roles for myosin II and phosphorylation of MLC in the formation of membrane blebs, and identify MLCK and Rho as key regulators of apoptotic blebbing. Thus, this report describes a model system for studying biochemical events that occur during the execution phase of apoptosis, and thus provides the first description of how MLCK and Rho signal transduction mechanisms regulate apoptotic membrane blebbing.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture
The PC6-3 subline of PC12 cells (Pittman et al., 1993) was cultured at 37°C with 5% CO2 in RPMI 1640 supplemented with 10% horse serum, 5% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin. COS-7 cells were cultured at 37°C with 5% CO2 in DME supplemented with 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin.
To remove serum, cells were trypsinized and washed three times in serum-free medium. Then 30,000 cells were plated per well in a 24-well tissue culture dish in serum-free medium with either 100 µM z-VAD-FMK, or an equivalent volume of the vehicle, DMSO. Control cells were washed and plated at the same density in serum-free N2 medium (5 µg/ml insulin, 30 nM selenium, 10 µg/ml transferrin, 20 nM progesterone, 100 µM putrescine, and 1 mg/ml BSA in RPMI 1640; Bottenstein et al., 1980), and then incubated with or without z-VAD-FMK. N2 medium prevents serum deprivation–induced cell death for up to 5 or 6 d (unpublished observations). STS (1 µM), and either 100 µM z-VAD-FMK or DMSO were added to cells plated in N2 medium. Cell viability was assessed by counting cells in randomly selected fields, in the presence of 0.0625% trypan blue. All experiments were also performed with the caspase inhibitor, BaF, with identical results.
The percentage of blebbing cells was determined for cells grown on collagen (50 µg/ml) coated 24-well tissue culture plates. Culturing cells on collagen provides a sharper distinction between normal wedge-shaped cells and round blebbing cells. An observer blinded to experimental condition counted all living cells and scored those with obvious membrane protrusions as blebbing. The effect of 5 µM KN-93, 30 µM H-89, 5 µM bisindolylmaleimide 1, 5 µM KT-5823, 4 µM KT-5926, 1 µM staurosporine, and 20 or 80 µM ML-9 on blebbing was determined by counting cells in the same fields before addition of drug, and 1 h after drug treatment. Six fields were counted per well, three wells per experiment, and experiments were performed three times.
The effects of cytoskeletal disruption on serum-deprived, z-VAD-FMK– treated cells were assessed by treating cells with cytochalasin D (0.5 µg/ml), taxol (100 µM), nocodazole (5 µM), and 2,3-butanedione monoxime (BDM; 15 mM). Drugs were added 24 h after serum removal and z-VAD-FMK administration, and cells were either counted 1 h later or, in the case of BDM experiments, cells were followed by time-lapse videomicroscopy.
DNA Laddering and Hoechst Staining
DNA laddering was performed as described previously (Pittman et al., 1993). Briefly, cells were either trypsinized or scraped directly into Eppendorf tubes (serum-free and staurosporine samples, respectively). Cell pellets were resuspended in 0.1 M EDTA, 1% SDS, 100 µg/ml proteinase K, and 0.2 M Tris, pH 8.5, and then incubated at 60°C for 2 h. After addition of 5 M potassium acetate, lysates were vortexed and placed on ice for 30 min. The supernatant obtained from centrifugation at 14,000 g for 15 min was precipitated with ice-cold ethanol, and DNA was electrophoresed.
For Hoechst staining after serum removal or staurosporine treatment, 300,000 cells were plated on collagen-coated, glass bottom 35-mm tissue culture dishes (Mat-Tek, Ashland, MA). After experimental treatments, cells were rinsed three times with PBS and then fixed for 15 min in 4% paraformaldehyde. Cells were rinsed with PBS three times, incubated with 5 µg/ml Hoechst 33342 in PBS for 15 min, rinsed once with PBS, coverslipped, and then allowed to dry for several hours.
Time-Lapse Videomicroscopy
Time-lapse videomicroscopy of cells was performed as described previously (Mills et al., 1995). Briefly, images were obtained with a video camera (AG-6050; Panasonic, Secaucus, NJ) attached to a Nikon Diaphot inverted microscope (Garden City, NJ), and recorded on either a JVC (BR-9000U; Pine Brook, NJ) or a Sony (SVT-5050; Park Ridge, NJ) time-lapse VHS VCR. Time-lapse images were then time-base corrected and digitized using Image 1 software (Universal Imaging, Inc., West Chester, PA). Culture conditions were identical to those in the incubator (5% CO2, 37°C), and cells could be recorded for at least 5 d without adverse effects. For time-lapse experiments,
200,000 cells were plated on 50 µg/ml collagen-coated, glass bottom 35-mm dishes. For assessment of drug effects, cells were transferred to the time-lapse chamber, and a field selected, and then recorded for at least 10 min (usually 30–60 min) before drug was added.
Phosphorylation of MLC
The procedure used was adapted from that described previously (Ludlowyke et al., 1989). Cells were labeled for 2 h in medium containing 100 µCi/ml [32P]orthophosphate, scraped into ice-cold PBS, and then pelleted 1 min at 12,000 g. The cell pellet was resuspended in ice-cold lysis buffer: 1% NP-40, 250 mM NaCl, 5 mM EGTA, 0.5 mM PMSF, 1 µg/ml leupeptin, 15 mM β-mercaptoethanol, 100 mM sodium pyrophosphate, 50 mM NaF, 20 mM Tris, pH 7.9. Lysates were homogenized through a 26-gauge needle until no longer viscous and then centrifuged at 14,000 g for 10 min. Cells lysates were treated with a 1:20 dilution of crude anti–myosin II antibody (obtained from Dr. R. Adelstein, National Institutes of Health, Bethesda, MD), and immune complexes isolated using protein A–Sepharose. Immunoprecipitates were then washed once in lysis buffer and once in PBS. For MLC separation and quantification, the method of Taylor and Stull (1988) was adapted as follows: immunoprecipitates were resuspended in 9 M urea, 2 mM DTT, 22 mM glycine, 20 mM sucrose, 1 mM EGTA, and 20 mM Tris, pH 8.8, and then heated to 90°C for 5 min. Samples were electrophoresed on a separating gel containing 10% acrylamide, 40% glycerol, 22 mM glycine, and 20 mM Tris, pH 8.8, after a stacking gel consisting of 4% acrylamide, 6 M urea, 22 mM glycine and 20 mM Tris, pH 8.8. Running buffer was 22 mM glycine and 20 mM Tris, pH 8.8. Gels were pre-electrophoresed for 1 h at 350 V with 1 mM DTT added to the upper chamber. Then samples were loaded and electrophoresed for 1.5 h at 450 V. Gels were dried and then exposed to PhosphorImager plates (Molecular Dynamics, Sunnyvale, CA). Bands were quantitated using ImageQuant software (Molecular Dynamics).
C3 Exoenzyme Experiments
The glutathione-S-transferase (GST) fusion protein of Clostridium botulinum C3 exoenzyme (construct obtained from Dr. A. Alberts, Imperial Cancer Research Fund, London, UK) was purified on glutathione Sepharose according to the manufacturer's instructions (Pharmacia Biotech, Uppsala, Sweden). Preliminary experiments were performed to determine optimal conditions for treating cells. Concentrations up to 25 µg/ml purified C3 in the presence or absence of 10 µg/ml lipofectamine as a vehicle for increasing cellular uptake were tested (Hirao et al., 1996). Concentrations of 10 µg/ml C3 transferase in 10 µg/ml lipofectamine or 25 µg/ml C3 transferase alone had marked biological effects on blebbing within 2 h. The C3/lipofectamine combination was used routinely in experiments. Counts of blebbing cells were made before and 2 h after addition of C3 and lipofectamine. Lipofectamine alone had no effect on blebbing.
| Results |
|---|
|
|
|---|
|
|
|
50% of the cells are dead (Fig. 1 a) or blebbing (Fig. 3 b) by 24 h. A similar asynchronous entry into blebbing is seen in serum-deprived, caspase-inhibited COS-7 cells, although the time-course is longer, and the proportion of blebbing cells is not as large (data not shown). In both cases, the morphology of blebbing in z-VAD-FMK–treated, serum-deprived cells is indistinguishable from that seen in the execution phase of apoptosis, except that, once these cells start to bleb, they continue to do so for hours to days rather than dying within the hour as serum-deprived cells without z-VAD-FMK do. Thus, treatment of apoptotic cultures with caspase inhibitors causes accumulation of blebbing cells not only in the Rat-1 fibroblast cell line as previously shown (McCarthy et al., 1997) but also in adrenal-derived PC12 cells, and kidney-derived COS-7 cells.
MLCK Activity Regulates Apoptotic Membrane Blebbing
As all other agents used to induce apoptosis in our laboratory (e.g., growth factor withdrawal, UV irradiation, H2O2, ceramide, and menadione) cause membrane blebbing, the absence of this feature of apoptosis in STS-treated cells was intriguing. Two hypotheses could explain this observation: (1) STS initiates apoptosis downstream of blebbing; or (2) STS initiates apoptosis upstream of blebbing but prevents blebbing by concomitantly inhibiting a necessary downstream kinase. To differentiate between these alternatives, cultures of PC12 and COS-7 cells were deprived of serum, and treated with z-VAD-FMK until a substantial portion of cells were actively blebbing (24 h of serum deprivation for PC12 cells and 48 h for COS-7 cells). Then STS was added and cells were followed using time-lapse videomicroscopy. Both PC12 and COS-7 cells stop blebbing within minutes after addition of STS (Fig. 4) but remain viable for hours. In other experiments, blebbing of UV-irradiated PC12 cells was also inhibited by STS treatment (data not shown), suggesting that the effect of STS is not limited to trophic factor withdrawal induced apoptotic blebbing.
|
|
|
|
60% (Fig. 8). Time-lapse videomicroscopy shows that overnight treatment with C3 completely inhibits blebbing without cell loss (data not shown).
|
|
| Discussion |
|---|
|
|
|---|
Apoptosis is a physiological process, defined by characteristic and evolutionarily conserved morphological changes including DNA laddering, chromatin condensation, membrane blebbing, cell shrinkage, and apoptotic body formation. Morphological events such as these distinguish apoptosis from other cellular processes; therefore, it is likely that these conserved features of apoptosis are critical aspects of the apoptotic process in vivo. Recently, there has been considerable interest in identifying mechanisms underlying these late processes (McCarthy et al., 1997; Rudel and Bokoch, 1997); however, the pathways that lead to these downstream events have been difficult to analyze biochemically because they occur asynchronously in a population of cells, with only
10% of cells in the execution phase at one time (Earnshaw, 1995; Mills et al., 1997; Messam and Pittman, 1998). Using z-VAD-FMK to inhibit death and synchronize cells early in the execution phase (i.e., before DNA laddering and chromatin condensation; McCarthy et al., 1997) has allowed us to characterize one of the hallmark features of apoptosis, membrane blebbing. This system should prove useful for continued characterization of regulatory mechanisms involved in blebbing, and for defining other signaling pathways activated during the execution phase of apoptosis.
A summary of our data in the context of the execution phase of apoptosis is provided in Fig. 9. An apoptotic stimulus (such as serum removal) activates several pathways that lead to a characteristic apoptotic death (i.e., DNA laddering, chromatin condensation, and membrane blebbing). Using caspase inhibitors to block cell death, a synchronous population of cells "trapped" early in the execution phase of apoptosis is generated, after initiation of blebbing, but before other characteristic changes such as chromatin condensation and DNA laddering (McCarthy et al., 1997). This system was used to demonstrate that MLC phosphorylation is crucial for membrane blebbing, as inhibition of MLCK (with STS, KT5926, ML-9, and ML-7) decreases blebbing, and phosphorylation of MLC is markedly enhanced in blebbing cells. Also, the small GTPase, Rho, which increases phosphorylation of MLC, was shown to be important for apoptotic membrane blebbing, as Rho inactivation also inhibits blebbing. Therefore, the data described in this paper provide starting points to begin elucidating upstream and downstream signaling events from MLCK and Rho during the execution phase of apoptosis.
|
The involvement of both MLCK and Rho signaling in the phosphorylation state of MLC may at first seem unnecessary, but this overlap in function may play an important regulatory role. For instance, MLCK could work synergistically with ROK. In this scenario, MLCK-stimulated phosphorylation of MLC may be increased by ROK-mediated inhibition of the myosin phosphatase. Here, the primary effect of ROK is the inhibition of myosin phosphatase, and the MLC phosphorylation by ROK may play a secondary role. Cells may need such a two-pronged approach on MLC phosphorylation to sustain the uninterrupted increase in cellular contractility that characterizes apoptotic blebbing. Another possibility is that, unlike MLCK (which requires calcium/calmodulin for activation), ROK function is not calcium-dependent. Thus, ROK phosphorylation of MLC may provide a calcium-independent mechanism for activation of myosin II.
The implication of myosin II in the mechanism of membrane blebbing, allows us to propose a working model of how early execution phase morphological changes occur in a cell. It has long been thought that myosin contraction of the peripheral actin ring produces centripetal force (Grebecki, 1994), which acts to compress the cytoplasm in the center of the cell. If structural proteins (such as ABP and fodrin) that link the cell membrane to the cortical actin layer are cleaved, then the centripetal force pushing the actin ring inward would cause extrusion of the cytoplasm in areas of weak actin/membrane linkage, resulting in bleb formation. To support this model for blebbing force production, we show that myosin II is necessary for blebbing.
Also supporting the model is the observation in the present study and in other reports (Keller and Zimmerman, 1986; Cotter et al., 1992; Ghibelli et al., 1995) that destabilization of actin filaments with cytochalasin greatly inhibits blebbing (cytochalasins can induce membrane bubbling in some non-apoptotic cells, but the morphological characteristics of this process are very different from those of apoptotic blebbing; Prentki et al., 1979, Miranda et al., 1974). Actin and fodrin are substrates for caspases (Martin et al., 1995; Cryns et al., 1996; Kayalar et al., 1996; Nath et al., 1996; Vanags et al., 1996; McCarthy et al., 1997); therefore, it has been speculated that caspase activation leading to actin and fodrin degradation, might lead to blebbing (Martin et al., 1995; Kayalar et al., 1996). However, data in this report and that of McCarthy et al. (1997) suggest that in these systems, blebbing is upstream of caspase inhibition. If this is true and our proposed working model is correct, then non-caspase–induced weaknesses in the cortical actin–membrane linkage must be occurring. Likely agents to perform this function would be calpains, which are known to cleave fodrin and other cytoskeletal proteins (Miyoshi et al., 1996; Nath et al., 1996). Inhibition of calpains prevents cleavage of the cytoskeletal proteins,
-actinin and talin, and also inhibits hepatocyte blebbing (Miyoshi et al., 1996). Preliminary data from our lab show that cells do not bleb if calpain inhibitors are added at the time of z-VAD-FMK treatment and serum removal (Stone, N.L., unpublished observations), which is consistent with the possibility that calpains are activated upstream of caspases and cleave key cytoskeletal proteins.
Destabilization of microtubules also may play an important role in the modulation of apoptotic blebbing. Treatment with nocodazole increases blebbing in our system and in others (Table I; Keller et al., 1985; Keller and Zimmerman, 1986). Consistent with this observation are studies showing that microtubules disassemble in the late stages of apoptosis (Bonfoco et al., 1996; Mills et al., 1998). Additional studies showing that microtubule disassembly increases cellular contractility (Danowski, 1989; Kolodney and Elson, 1993), and that this increase in contractility is mediated by an increase in MLC phosphorylation (Kolodney and Elson, 1995) support our working model of force generation for membrane blebbing.
Apoptotic membrane blebbing is a combination of dynamic protrusion and retraction events. MLCK inhibitors decrease the fraction of cells with blebs in static cell– counting experiments and lead to a loss of blebs in time-lapse videomicroscopy studies. Thus, inhibition of myosin II activity seems to prevent further protrusion of blebs, whereas retraction of blebs is not affected by inhibition of MLCK. However, both protrusion and retraction of blebs are slowed or stopped by the low affinity inhibitor of the myosin ATPase, BDM. BDM inhibits unconventional myosins as well as myosin II. Therefore, inhibition of bleb retraction by BDM suggests that a form of unconventional myosin may be responsible for retracting blebs. Interestingly, similar observations with BDM and MLCK inhibitors on growth cone protrusion and retraction have been observed recently (Ruchhoeff and Harris, 1997).
In addition to regulating blebbing, myosin and Rho activity may be involved in mediating other functions during the execution phase of apoptosis. The first morphological sign of apoptosis in vivo is a pulling up and away (rounding up) from extracellular matrix attachments. Cell contraction is mediated by Rho in cells that don't have strong adhesions to extracellular matrix, like PC12 cells (Jalink et al., 1994; Tigyi et al., 1996). In epithelial cell monolayers, individual apoptotic cells contract, using an actin-dependent mechanism to pull on neighboring cells (Peralta-Soler et al., 1996). Because intercellular attachments are maintained, this contraction performs the important function of automatically closing gaps that would be formed by death of a cell. Thus, actin-based contraction (likely involving Rho/ myosin regulation) could serve crucial in vivo functions, by preventing gaps in epithelia or mechanically recruiting neighboring cells to phagocytose apoptotic cells.
This is the first report to define a potential mechanism for myosin II–mediated force generation during apoptotic membrane blebbing and to propose a working model of how blebbing might occur. Synchronizing cells early in the final phase of apoptosis will facilitate future characterization of myosin and Rho in bleb protrusion, as well as providing a powerful system for studying upstream and downstream signaling pathways involved in other conserved events in the execution phase of apoptosis. Thus, this study advances our understanding of the signaling events that occur during apoptosis, and describes the use of a model system that will allow other features of the execution phase of apoptosis to be understood mechanistically.
| Acknowledgments |
|---|
This work was supported by National Institutes of Health grant NS 32465 (to R.N. Pittman) and MSTP 5-T32-6M07170 (to J.C. Mills).
Submitted: 19 September 1997
Revised: 10 December 1997
J.C. Mills and N.L. Stone contributed equally to this work.
| References |
|---|
|
|
|---|
Aktories K, Mohr C & Koch G. Clostridium botulinum C3 ADP- ribosyltransferase, Curr Top Micro Immunol, 1992, 175, 115–131.[Medline]
Alessi D, Macdougall LK, Sola MM, Ikebe M & Cohen P. The control of protein phospatase-1 by targeting subunits. The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1, Eur J Biochem, 1992, 210, 1023–1035.[Medline]
Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y & Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase), J Biol Chem, 1996, 271, 20246–20249.
Bonfoco E, Leist M, Zhivotovsky B, Orrenius S, Lipton SA & Nicotera P. Cytoskeletal breakdown and apoptosis elicited by NO donors in cerebellar granule cells require NMDA receptor activation, J Neurochem, 1996, 67, 2484–2493.[Medline]
Bottenstein JE, Skaper SD, Varon SS & Sato GH. Selective survival of neurons from chick embryo sensory ganglionic dissociates utilizing serum-free supplemented medium, Exp Cell Res, 1980, 125, 183–190.[Medline]
Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T & Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), PC12D pheochromocytoma cells, J Biol Chem, 1990, 265, 5267–5272.
Chinnaiyan AM & Dixit VM. The cell-death machine, Curr Biol, 1996, 6, 555–562.[Medline]
Chrzanowska-Wodnicka M & Burridge K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions, J Cell Biol, 1996, 133, 1403–1415.
Cotter TG, Lennon SV, Glynn JM & Green DR. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis, Cancer Res, 1992, 52, 997–1005.
Cryns, V.L., Bergeron L., Zhu H., Li H., and Yuan J. 1996. Specific cleavage of
-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1β-converting enzyme/Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease. J. Biol. Chem. 271:31277–31282.
Cunningham CC. Actin polymerization and intracellular solvent flow in cell surface blebbing, J Cell Biol, 1995, 129, 1589–1599.
Cunningham CC, Gorlin JB, Kwiatkowski DJ, Hartwig JH, Janmey PA, Byers R & Stossel TP. Actin-binding protein requirement for cortical stability and efficient locomotion, Science, 1992, 255, 325–327.
Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS & Spiegel S. Suppression of ceramide-mediated programmed cell death by spingosine-1-phosphate, Nature, 1996, 381, 800–803.[Medline]
Danowski BA. Fibroblast contractility and actin organization are stimulated by microtubule inhibitors, J Cell Science, 1989, 93, 255–266.
Deery WJ & Heath JP. Phagocytosis induced by thyrotropin in cultured thyroid cells is associated with myosin light chain dephosphorylation and stress fiber disruption, J Cell Biol, 1993, 122, 21–37.
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR & Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt, Science, 1997, 275, 661–665.
Earnshaw WC. Nuclear changes in apoptosis, Curr Opin Cell Biol, 1995, 7, 337–343.[Medline]
Fishkind DJ, Cao L & Wang Y. Microinjection of the catalytic fragment of myosin light chain kinase into dividing cells:Effects on mitosis and cytokinesis, J Cell Biol, 1991, 114, 967–975.
Gallagher PJ, Herring BP & Stull JT. Myosin light chain kinases, J Muscle Res Cell Motil, 1997, 18, 1–16.[Medline]
Gebbink MFBG, Kranenburg O, Poland M, van Horck FPG, Houssa B & Moolenaar WH. Identification of a novel, putative Rho-specific GDP/GTP exchange factor and a RhoA-binding protein: Control of neuronal morphology, J Cell Biol, 1997, 137, 1603–1613.
Ghibelli L, Nosseri C, Coppola S, Maresca V & Dini L. The increase in H2O2-induced apoptosis by ADP-ribosylation inhibitors is related to cell blebbing, Exper Cell Res, 1995, 221, 470–477.[Medline]
Grebecki A. Membrane and cytoskeleton flow in motile cells with emphasis on the contribution of free-living amoebae, Int Rev Cytol, 1994, 148, 37–80.
Hashimoto Y, Nakayama T, Teramoto T, Kato H, Watanabe T, Kinoshita M, Tsukamoto K, Tokunaga K, Kurokawa K, Nakanishi S et al.. Potent and preferential inhibition of Ca2+/calmodulin-dependent protein kinase II by K252a and its derivative, KT5926, Biochem Biophys Res Commun, 1991, 181, 423–429.[Medline]
Hirao M, Sato N, Kondo T, Yonemura S, Monden M, Sasaki T, Takai Y & Tsukita S. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway, J Cell Biol, 1996, 135, 37–51.
Hubbard MJ & Cohen P. On target with a new mechanism for the regulation of protein phosphorylation, Trends Biochem Sci, 1993, 18, 172–177.[Medline]
Ichijo H, Nishida E, Irie K, Ten P, Dijke, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K & Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways, Science, 1997, 275, 90–94.
Jacobson MD, Weil M & Raff MC. Programmed cell death in animal development, Cell, 1997, 88, 347–354.[Medline]
Jalink K, van Corven EJ, Hengeveld T, Morii N, Narumiya S & Moolinaar WH. Inhibition of lysophosphatide- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho, J Cell Biol, 1994, 126, 801–810.
Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI & Johnson GL. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death, J Biol Chem, 1996, 271, 3229–3237.
Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J & Evan G. Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB, Nature, 1997, 385, 544–548.[Medline]
Kayalar C, Ord T, Testa MP, Zhong L-T & Bredesen DE. Cleavage of actin by interleukin 1β-converting enzyme to reverse DNaseI inhibition, Proc Natl Acad Sci USA, 1996, 93, 2234–2238.
Keller HU & Zimmermann A. Shape changes and chemotaxis of Walker 256 carcinosarcoma cells in response to colchicine, vinblastine, nocodazole, and taxol, Invasion and Metastasis, 1986, 6, 33–43.[Medline]
Keller HU, Zimmermann A & Cottier H. Phorbol myristate acetate (PMA) suppresses polarization and locomotion and alters F-actin content of Walker carcinosarcoma cells, Int J Cancer, 1985, 36, 495–501.[Medline]
Kimura K, Iho M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K et al.. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase), Science, 1996, 273, 245–248.[Abstract]
Kohama K, Ye LH, Hayakawa K & Okagaki T. Myosin light chain kinase: an actin-binding protein that regulates an ATP-dependent interaction with myosin, Trends Pharmacol Sci, 1996, 17, 284–287.[Medline]
Kolodney MS & Elson EL. Correlation of myosin light chain phosphorylation with isometric contraction of fibroblasts, J BiolChem, 1993, 268, 23850–23855.
Kolodney MS & Elson EL. Contraction due to microtubule disruption is associated with increased phosphorylation of myosin regulatory light chain, Proc Natl Acad Sci USA, 1995, 92, 10252–10256.
Laster SM & Mackenzie JM Jr. Bleb formation and F-actin distribution during mitosis and tumor necrosis factor-induced apoptosis, Microscopy Res Tech, 1996, 34, 272–280.[Medline]
Lazebnik, Y.A., A. Takahashi, G.G. Poirier, S.H. Kaufman, and W.C. Earnshaw. 1995. Characterization of the execution phase of apoptosis in vitro using extracts from condemned-phase cells. J. Cell Sci. Suppl. 19:41–49.
Ludowyke RI, Peleg I, Beaven MA & Adelstein RS. Antigen- induced secretion of histamine and the phosphorylation of myosin by protein kinase C in rat basophilic leukemia cells, J Biol Chem, 1989, 264, 12492–12501.
Maciver SK. Myosin II function in nonmuscle cells, Bioessays, 1996, 18, 179–182.[Medline]
Martin SJ, O'Brien GA, Nishioka WK, McGahon AJ, Mahboubi A, Saido TC & Green DR. Proteolysis of fodrin (non-erythroid spectrin) during apoptosis, J Biol Chem, 1995, 270, 6425–6428.
Mashima T, Naito M, Fujita N, Noguchi K & Tsuruo T. Identification of actin as a substrate of ICE and an ICE-like protease and involvement of an ICE-like protease but not ICE in VP-16-induced U937 apoptosis, Biochem Biophys Res Comm, 1995, 217, 1185–1192.[Medline]
McCarthy NJ, Whyte MKB, Gilbert CS & Evan GI. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak, J Cell Biol, 1997, 136, 215–227.
Messam, C.A., and R.N. Pittman. 1998. Asynchrony and commitment to die during apoptosis. Exp. Cell Res. In Press.
Mills J C, Wang S L, Erecinska M & Pittman R N. Use of cultured neurons and neuronal cell lines to study morphological, biochemical, and molecular changes occurring in cell death, Methods Cell Biol, 1995, 46, 217–242.[Medline]
Mills JC, Kim LH & Pittman RN. Differentiation to an NGF- dependent state and apoptosis following NGF removal both occur asynchronously in cultures of PC12 cells, Exp Cell Res, 1997, 231, 337–345.[Medline]
Mills, J.C., V.M.-Y. Lee, and R.N. Pittman. 1998. Activation of a PP2A-like phosphatase and dephosphorylation of
protein characterize onset of the execution phase of apoptosis. J. Cell Sci. In press.
Miranda A, Godman GC, Deitch AD & Tanenbaum SW. Action of cytochalasin D on cells of established lines, J Cell Biol, 1974, 61, 481–500.
Mitchison TJ & Cramer LP. Actin-based cell motility and cell locomotion, Cell, 1996, 84, 371–379.[Medline]
Miyoshi H, Umeshita K, Sakon M, Imajoh-Ohmi S, Fujitani K, Gotoh M, Oiki E, Kambayashi J & Monden M. Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury, Gastroenterology, 1996, 110, 1897–1904.[Medline]
Nagata S. Apoptosis by death factor, Cell, 1997, 88, 355–365.[Medline]
Nath R, Raser KJ, Stafford D, Hajimohammadreza I, Posner A, Allen H, Talanian RV, Yuen P, Gilbertsen RB & Wang KK. Non-erythroid
-spectrin breakdown by calpain and interleukin 1 β-converting-enzyme-like protease(s) in apoptotic cells:contributory roles of both protease families in neuronal apoptosis, Biochem J, 1996, 319, 683–690.[Medline]
Nicholson DW & Thornberry NA. Caspases: killer proteases, Trends Biochem Sci, 1997, 22, 299–306.[Medline]
Noda M, Yasuda-Fukazawa C, Moriishi K, Kato T, Okuda T, Kurokawa K & Takuwa Y. Involvement of Rho in GTP
S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity, FEBS (Fed Eur Biochem Sci) Lett, 1995, 367, 246–250.
Park DS, Stefanis L, Yan CYI, Farinelli SE & Greene LA. Ordering the cell death pathway, J Biol Chem, 1996, 271, 21898–21905.
Paterson HF, Self A, Garrett MD, Just I, Aktories K & Hall A. Microinjection of recombinant p21 Rho induces rapid changes in cell morphology, J Cell Biol, 1990, 111, 1001–1007.
Peralta-Soler A, Mullin JM, Knudsen KA & Marano CW. Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells, Am J Physiol, 1996, 270, 869–879.
Pittman RN, Wang SL, DiBenedetto AJ & Mills JC. A system for characterizing cellular and molecular events in programmed neuronal cell death, J Neurosci, 1993, 13, 3669–3680.[Abstract]
Pitzer F, Dantes A, Fuchs T, Baumeister W & Amsterdam A. Removal of proteosomes from the nucleus and their accumulation in apoptotic blebs during programmed cell death, FEBS (Fed Eur Biochem Sci) Lett, 1996, 394, 47–50.
Prentki M, Chaponnier C, Jeanrenaud B & Gabbiani G. Actin microfilaments, cell shape, and secretory processes in isolated rat hepatocytes, J Cell Biol, 1979, 81, 592–607.
Ridley AJ & Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors, Cell, 1992, 70, 389–399.[Medline]
Ruchhoeff ML & Harris WA. Myosin functions in Xenopus retinal ganglion cell growth cone motility in vivo, J Neurobiol, 1997, 32, 567–578.[Medline]
Rudel T & Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2, Science, 1997, 276, 1571–1574.
Saitoh M, Naka M & Hidaka H. The modulatory role of myosin light chain phosphorylation in human platelet activation, Biochem Biophys Res Commun, 1986, 140, 280–287.[Medline]
Saitoh M, Ishikawa T, Matsushima S, Naka M & Hidaka H. Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase, J Biol Chem, 1987, 262, 7796–7801.
Sekine A, Fujiwara M & Narumiya S. Asparagine residue in the Rho gene product is the modification site for botulinum ADP-ribosyltransferase, J Biol Chem, 1989, 264, 8602–8605.
Song, Q., T. Wei, S. Lees-Miller, E. Alnemri, D. Watters, and M.F. Lavin. 1997. Resistance of actin to cleavage during apoptosis. Proc. Natl. Acad. Sci. USA. 94:157–162.
Taylor DA & Stull JT. Calcium dependence of myosin light chain phosphorylation in smooth muscle cells, J Biol Chem, 1988, 263, 14456–14462.
Tigyi G, Fischer DJ, Sebok A, Yang C, Dyer DL & Miledi R. Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho, J Neurochem, 1996, 66, 537–548.[Medline]
Vanags DM, Porn-Ares MI, Coppola S, Burgess DH & Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis, J Biol Chem, 1996, 271, 31075–31085.
Vemuri GS, Zhang J, Huang R, Keen JH & Rittenhouse SE. Thrombin stimulates wortmannin-inhibitable phosphoinositide 3-kinase and membrane blebbing in CHRF-288 cells, Biochem J, 1996, 314, 805–810.[Medline]
Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z & Kolesnick RN. Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis, Nature, 1996, 380, 75–79.[Medline]
Wyllie AH, Kerr JFR & Currie AR. Cell death: the significance of apoptosis, Int Rev Cytol, 1980, 68, 251–306.[Medline]
Xia Z, Dickens M, Raingeaud J, Davis RJ & Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis, Science, 1995, 270, 1326–1331.
Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles LA, Zon L, Kyriakis J, Liu F-F & Woodgett JR. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat, Curr Biol, 1996, 6, 606–613.[Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|